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An evaluation of the effect of 1 year of a gluten-free
diet was performed in patients with irritable bowel
syndrome and fibromyalgia syndrome displaying
lymphocytic enteritis. Gluten withdrawal produced a
slight but significant improvement of the functional
symptoms, suggesting that gluten might be partly
responsible for this clinical picture. This hypothesis
should be confirmed by a double-blind placebo-
controlled trial since it cannot be ruled out that the
studied patients displayed a subjective sensation of
improvement due to the placebo effect of gluten
withdrawal. Further investigations are needed before
recommending gluten withdrawal in patients with
fibromyalgia and lymphocytic enteritis.vey of 486 patients with nonceliac gluten sensitivity, IBSIn their paper published in a recent issue of Arthritis Re-
search and Therapy, Rodrigo and colleagues evaluated
the effect of 1 year of a gluten-free diet on the clinical
evolution of irritable bowel syndrome (IBS) plus fibro-
myalgia syndrome (FMS) in patients with lymphocytic
enteritis (LE) [1]. The study sample included 97 adult
females with IBS and FMS, of whom 58 had LE and the
remaining 39 had a normal intraepithelial lymphocytic
(IEL) count. All subjects fulfilled the Rome III criteria
for IBS and the American College of Rheumatology
1990 criteria for FMS and none of them satisfied the
diagnostic criteria for celiac disease diagnosis (absence
of villous atrophy and negativity for tissue transglutami-
nase antibodies).
IBS and FMS are two chronic functional disorders that
are found in a high number of people in the generalCorrespondence: umberto.volta@aosp.bo.it
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unless otherwise stated.population and are frequently detected in the same subject
[2]. A subset of patients complaining of IBS and FMS dis-
plays LE, a morphological finding that by itself is not spe-
cific for celiac disease, also being found in many other
pathological conditions such as food allergy, autoimmune
disorders, Helicobacter pylori infection, nonsteroidal anti-
inflammatory drug treatment and common variable im-
munodeficiency [3].
The spectrum of gluten-related disorders has recently
acquired a new syndrome, defined as nonceliac gluten sen-
sitivity according to the criteria established in the two
Consensus Conferences held in London and Munich [4].
This new clinical entity is characterized by IBS-like symp-
toms and several extraintestinal manifestations occurring
after gluten ingestion in patients without celiac disease
and wheat allergy. In a recent prospective multicenter sur-
and FMS were respectively detected in 47% and 31% of
cases and about one-third of these patients had LE [5].
Along with IBS-related and FMS-related symptoms,
the patients studied by Rodrigo and colleagues also showed
other manifestations resembling the clinical picture of non-
celiac gluten sensitivity such as skin rash, cognitive dys-
function, headache, numbness, anxiety and depression [1].
In Rodrigo and colleagues’ paper, the gluten-free diet
produced a slight but significant improvement of both IBS-
related (chronic abdominal pain, changes in intestinal habit,
bloating) and FMS-related symptoms (chronic widespread
pain, generalized tender points, fatigue and restless sleep)
in the LE subgroup versus the non-LE subgroup. These re-
sults stress the potential role of gluten as a trigger of the
clinical manifestations of IBS and FMS and indicate that LE
might be useful to identify those patients who potentially
benefit from gluten withdrawal. One relevant limitation of
this study is the lack of a double-blind placebo-controlled
challenge, which is the only procedure to confirm the rolean Open Access article distributed under the terms of the Creative Commons
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manifestations. Indeed, it cannot be ruled out that some pa-
tients displayed a subjective sensation of improvement due
to the placebo effect of a gluten-free diet [6]. The search for
antigliadin antibodies could be of help to elucidate whether
gluten can be partly responsible for the clinical picture
observed in Rodrigo and colleagues’ patients. Indeed, anti-
gliadin antibodies (particularly those belonging to the IgG
class) are the only marker observed in patients with symp-
toms elicited by gluten ingestion, being positive in more
than 50% of cases [7]. These antibodies are not specific for
gluten-related symptoms, but their finding in patients with
symptoms potentially evoked by gluten ingestion should be
regarded as an indication for a gluten-free diet trial in
patients with LE [8]. Antigliadin antibodies of the IgG
class are closely related to the gluten-induced symptoms
and tend to disappear very quickly (within a few weeks)
together with the remission of symptoms after a gluten-
free diet [9].
An interesting finding emerging from the Spanish study
is that about 20% of IBS/FMS patients with LE had rela-
tives with celiac disease, whereas no familial case of celiac
disease was observed among patients without LE [1]. In
the same guise, familial cases of FMS were found, although
to a lesser extent, only in the group with LE (7%). These
data suggest that first-degree relatives of IBS/FMS patients
with LE should be carefully investigated for the possible
presence of undetected cases of celiac disease and FMS.
For LE, the mean IEL number reported in Rodrigo and col-
leagues’ paper was 35/100. This result confirms that LE
found in gluten-sensitive patients is mild, with a lower
mean IEL number than that usually observed in celiac dis-
ease patients (usually >40/100) [10].
The caution in the conclusions of Rodrigo and col-
leagues’ study is appreciable and shareable. A gluten-free
diet is not appropriate in patients with IBS/FMS with
normal intestinal mucosa (normal IEL count). Moreover,
although the reported results suggest a significant im-
provement of symptomatology after a gluten-free diet in
the LE subgroup, further studies including double-blind
placebo-controlled trials are needed before proposing
gluten withdrawal in IBS/FMS patients with LE.
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